Loading...
•
Sep 30, 2021
Sana Q3 2021 Earnings Report
Sana Biotechnology reported financial results for the third quarter of 2021 and provided business updates.
Key Takeaways
Sana Biotechnology reported a net loss of $83.3 million, or $0.46 per share, for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $866.1 million as of September 30, 2021. Sana also announced a license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.
Announced license agreement for Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.
Cash position of $866.1 million as of September 30, 2021.
Progressing pipeline and growing people and capabilities.
Looking forward to presenting data from in vivo CAR T and ex vivo allogeneic CAR T cell programs at ASH Annual Meeting & Exposition in December.
Forward Guidance
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...